Patents by Inventor Hongying Mo

Hongying Mo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S-(carboxymethyl)-cysteine pharmaceutical compound and preparation method and use thereof
    Patent number: 10251854
    Abstract: Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 9, 2019
    Assignees: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Baiyunshan Pharmaceutical General Factroy Guangzhou Institute of Respiratory Disease
    Inventors: Mao Chen, Shaoxuan Zhu, Ping Wan, Wei Wang, Wei Liao, Hairong Hu, Xianglin Fu, Jin Feng, Binge Huang, Lin Zhang, Nanshan Zhong, Jinping Zheng, Hongying Mo
  • S-(CARBOXYMETHYL)-CYSTEINE PHARMACEUTICAL COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20170333374
    Abstract: Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.
    Type: Application
    Filed: July 5, 2013
    Publication date: November 23, 2017
    Applicants: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Baiyunshan Pharmaceutical General Factory, Guangzhou Institute of Respiratory Disease
    Inventors: Mao Chen, Shaoxuan Zhu, Ping Wan, Wei Wang, Wei Liao, Hairong Hu, Xianglin Fu, Jin Feng, Binge Huang, Lin Zhang, Nanshan Zhong, Jinping Zheng, Hongying Mo